A s part of the American Rescue Plan Act of 2021, the federal government announced more than 1 billion dollars in new funding to support the disease intervention specialist (DIS) workforce. 1 As this funding is dispersed, state and local public health officials will decide how to best use it to advance public health goals, given budget and workforce constraints. Decisions on how to develop and implement a program or intervention are made in consideration of these resource limitations, and cost-effectiveness analysis (CEA) provides a framework for guiding this decision-making process.Cost-effectiveness analysis is motivated by the need to maximize some health outcome given a limited set of resources or, conversely, to minimize the costs to achieve a particular health goal. 2 In essence, CEA quantifies trade-offs between the costs and benefits of a health intervention. A core concept in CEA is the idea of opportunity costs, or the value of potential alternative uses of a resource. 3 We typically want to avoid using limited resources on an activity if an alternative use of these resources could result in larger health gains. Costs of an intervention are measured in dollars, and benefits are measured in terms of a health outcome of interest. The costs and benefits of each intervention are then compared, and interventions that yield greater health gains per dollar spent should thus be prioritized, all else being equal.Disease intervention specialist may engage in a variety of different activities that go well beyond sexually transmitted infection (STI) partner notification. The overall benefits of having a strong DIS workforce are broad and difficult to quantify. Rather than estimating the full benefits of DIS, this commentary will focus on using CEA methods to help decision makers prioritize DIS activities.